Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $19.00 Consensus Price Target from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $19.00.

Several research analysts have recently commented on the company. HC Wainwright reduced their target price on Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. JMP Securities cut their target price on shares of Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a research note on Tuesday, May 7th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Thursday, February 8th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. grew its position in Enanta Pharmaceuticals by 613.6% during the third quarter. Assenagon Asset Management S.A. now owns 631,626 shares of the biotechnology company’s stock worth $7,055,000 after buying an additional 543,111 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Enanta Pharmaceuticals by 445.6% in the third quarter. Acadian Asset Management LLC now owns 548,782 shares of the biotechnology company’s stock worth $6,125,000 after purchasing an additional 448,201 shares during the period. Vanguard Group Inc. raised its stake in Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Federated Hermes Inc. bought a new stake in Enanta Pharmaceuticals during the fourth quarter worth about $1,253,000. Finally, Trexquant Investment LP acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $1,481,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $12.47 on Wednesday. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $28.25. The company has a market capitalization of $264.11 million, a P/E ratio of -2.00 and a beta of 0.54. The company has a 50-day simple moving average of $14.45 and a 200 day simple moving average of $12.36.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.